Articles

Nvidia and Meta are 2 reasons why the Dow lags the S&P 500 by double-digits

Only four of the 10 largest S&P 500 stocks are in the Dow.

Medical-device makers ResMed and Inspire slump after Lilly’s Zepbound trial shows benefits for sleep apnea

ResMed and Inspire Medical make devices that help patients with sleep apnea breathe better.

Trump beats Biden for ‘king of debt’ title as market braces for crush of federal bonds

Excluding COVID stimulus money, President Trump approved $4.8 trillion in new debt to President Biden’s $2.2 trillion.

Nvidia’s stock set to enter correction territory as chip-sector selloff sustains

The three-day slide in Nvidia shares is on track to shave more than $400 billion off the company’s market capitalization.

11 favored semiconductor stocks expected to outperform Nvidia over the next year

Nvidia Corp. dominates coverage of the semiconductor industry, but there are other semiconductor manufacturers that are also growing quickly during this upcycle for the industry.

Nvidia is ‘both king and kingmaker,’ and these chip stocks could pop in its wake

Marvell and Astera Labs can continue growing alongside Nvidia, according to Jefferies.

AI revolution is still a long way off, Oaktree founder Howard Marks says

Howard Marks said he believes it will take a good amount of time before AI technologies start impacting non-AI companies.

Fed’s Goolsbee lays out dovish case for potential rate cuts and flags ‘a couple of warning signs’ on economy

Chicago Fed President Austan Goolsbee said Monday there are new signs of stress on the economy that should make the U.S. central bank at least wonder if its policy rate needs to be as high as it currently is.

A former Estée Lauder executive wanted to create a Harvard scholarship for students of Armenian descent. The school turned her down.

The case comes as scholarships tied to race and ethnicity are posing challenges to donors and schools in the wake of the Supreme Court’s affirmative action decision

Alnylam’s stock surges as heart drug vies with a Pfizer blockbuster

Alnylam Pharmaceuticals’ stock jumped nearly 40% premarket on Monday after the company released results of a late-stage trial for a heart drug that analysts see competing with a key Pfizer treatment.

Ally Financial draws praise as well-positioned for soft landing in Citi’s new ‘buy’ rating

Analyst Keith Horowitz said Ally Financial offers “the best way” to play an economic recovery within Citi’s coverage universe due to “fixed rate asset repricing potential combined with a liability sensitive balance sheet.”

Apple’s stock is up 25% from its April low. Here’s how it can gain another 25%.

An analyst thinks Wall Street still underestimates AI’s potential to drive iPhone device upgrades.
1 1,034 1,035 1,036 1,037 1,038 2,311